John C. Reed - 15 Feb 2025 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Innovative Medicine, R&D
Signature
/s/ Laura H. McFalls, as attorney-in-fact for John C. Reed
Issuer symbol
JNJ
Transactions as of
15 Feb 2025
Net transactions value
-$60,118
Form type
4
Filing time
18 Feb 2025, 21:11:45 UTC
Previous filing
31 Oct 2024
Next filing
05 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +1,350 +9.3% $0.000000 15,927 15 Feb 2025 Direct F1
transaction JNJ Common Stock Tax liability $60,118 -385 -2.4% $156.15 15,542 18 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -1,350 -33% $0.000000 2,698 15 Feb 2025 Common Stock 1,350 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of RSUs.
F3 Each RSU represents a contingent right to receive one share of Company Common Stock.